| Company Name: | Kosan Biosciences Inc | | Ticker Symbol: | KOSN | | | WWW Address: | www.kosan.com | | CEO: | Helen S. Kim | | No. of Employees: | 91 | | Common Issue Type: | CS | | Business Description: | A cancer therapeutics company focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90, or Hsp90, inhibitors and epothilones.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 5.63 |  0.0 | - | - | 0 | 5.63 | 5.48 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 240.4 | 42.7 | 3.55 | -0.69 | 0.00 | 0.0 | 0.0 | 6.40 - 1.28 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 5.63 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 240.2 | mil |
| Latest Shares Outstanding | 42.7 | mil |
| Earnings pS (EPS) | -0.69 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 249,527 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 38.9 | mil |
| Float as % of Shares Outstanding | 91.2 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 61.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 340.00 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.2 | % |
| Return on Assets (ROA) | -60.4 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -76.7 | % |
| Current Ratio | 4.3 | |
| Leverage Ratio (Assets/Equity) | 1.3 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.02 | |
| LT Debt/Total Capital | 1.0 | % |
| Working Capital pS | 1.07 | $ |
| Cash pS | 1.02 | $ |
| Book-Value pS | 1.21 | $ |
| Tangible Book-Value pS | 1.21 | $ |
| Cash Flow pS | -0.93 | $ |
| Free Cash Flow pS | -0.94 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 4.65 | |
| Price/Tangible Book Ratio | 4.65 | |
| Price/Cash Flow | -6.1 | |
| Price/Free Cash Flow | -6.0 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 2.6 | 106 | 3,630 | 16,779 |
| 4 Weeks | 5.63 | 5.39 | 5.42 | 3.9 | 114 | 7,617 | 152,339 |
| 13 Weeks | 5.63 | 1.42 | 1.71 | 229.2 | 339 | 6,531 | 417,984 |
| 26 Weeks | 5.63 | 1.28 | 3.80 | 48.2 | 171 | 4,407 | 550,893 |
| 52 Weeks | 6.40 | 1.28 | 5.22 | 7.9 | 127 | 3,103 | 778,755 |
| YTD | 5.63 | 1.28 | - | 56.4 | 180 | 4,426 | 548,766 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 5.55 | 5.51 | 3.40 | 2.90 | 3.53 | 3.55 | 5.19 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -3.18 | 2.9 | 3.84 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -20.30 | NA | -9.64 |
| R&D | 7.17 | NA | 5.92 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -64.0 | -64.0 | 68.1 |
| Earnings % | -100.0 | -100.0 | 0.0 |
| EPS % | -100.0 | -100.0 | 0.0 |
| EPS $ | -0.27 | -0.27 | 0.19 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 69.63 |
| Current Ratio | 4.1 |
| Quick Ratio (Acid Test) | 4.0 |
| Liquidity Ratio (Cash) | 3.98 |
| Receivables Turnover | 18.5 |
| Average Collection Period | 19 |
| Working Capital/Equity | 91.0 |
| Working Capital pS | 1.27 |
| Cash-Flow pS | -0.64 |
| Free Cash-Flow pS | -0.86 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 7.29 |
| Financial Leverage Ratio (Assets/Equity) | 1.3 |
| Debt Ratio | 23.5 |
| Total Debt/Equity (Gearing Ratio) | 0.03 |
| LT Debt/Equity | 0.01 |
| LT Debt/Capital Invested | 1.2 |
| LT Debt/Total Liabilities | 3.8 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.38 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 1.30 |
| Tobin's Q Ratio | 3.08 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -6.04 |
| Enterprise Value (EV)/Free Cash Flow | -5.28 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 4.65 |
| Price/Book Ratio - LTM | 4.65 |
| Price/Cash Flow Ratio | -6.1 |
| Price/Free Cash Flow Ratio - LTM | -6.0 |
| Price/Sales Ratio | 16.56 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.02 |
| Current Liabilities pS | 0.41 |
| Tangible Book Value pS - LTM | 1.21 |
| Book Value pS - LTM | 1.21 |
| Capital Invested pS | 1.41 |
| Cash pS - LTM | 1.02 |
| Cash Flow pS - LTM | -0.93 |
| Free Cash Flow pS - LTM | -0.94 |
| Earnings pS (EPS) | -0.69 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -160.99 |
| Free Cash Flow Margin 5YEAR AVG | -120.33 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.38 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.38 |
| Return on Capital Invested (ROCI) | -47.6 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -38.6 |
| Assets Productivity | 0.30 |
| Return on Assets (ROA) | -36.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | -27.5 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 21 |
| Revenue per Employee | 249,527 |
| Net Income per Employee | -314,923 |
| Average Collection Period | 21 |
| Receivables Turnover | 18.5 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 12.51 |
| Assets/Revenue | 3.33 |
| Net Working Capital Turnover | 0.42 |
| Fixed Assets Turnover | 3.76 |
| Total Assets Turnover | 0.3 |
| Revenue per $ Cash | 0.48 |
| Revenue per $ Plant | 4.68 |
| Revenue per $ Common Equity | 0.38 |
| Revenue per $ Capital Invested | 0.38 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 35.9 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 31.9 |
| Research & Devlopment (R&D) as % of Revenue | 208.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 208.2 |
|
|  
|
| |
 |  |